Amplify Treatments, Testing and Advancements ETF (GERM) Price, Holdings, & News

ETF Overview

The ETFMG Treatments, Testing and Advancements ETF (GERM) is an exchange-traded fund that mostly invests in health care equity. The fund tracks a tier-weighted, narrow index of US-listed, global biotech companies that are engaged in the testing and treatments of infectious diseases. GERM was launched on Jun 17, 2020 and is managed by ETF Managers Group.

Key Stats

• Today's Range: $19.16 to $19.16
• 50-Day Range: $19.16 to $19.16
• 52-Week Range: $15.67 to $20.20
• Volume: N/A
• Average Volume: 1,891 shs
• Market Capitalization: $10.54 million
• Assets Under Management: $9.67 million
• Dividend Yield: 0.73%
• Net Expense Ratio: 0.68%
• Aggregate Rating: N/A

GERM ETF - Frequently Asked Questions

How have GERM shares performed this year?

Amplify Treatments, Testing and Advancements ETF's stock was trading at $19.1577 on January 1st, 2025. Since then, GERM stock has increased by 0.0% and is now trading at $19.1577.
View the best growth stocks for 2025 here.

How do I buy shares of Amplify Treatments, Testing and Advancements ETF?

Shares of GERM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Amplify Treatments, Testing and Advancements ETF own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Amplify Treatments, Testing and Advancements ETF investors own include Moderna (MRNA), PayPal (PYPL), Global X Robotics & Artificial Intelligence Thematic ETF (BOTZ), Walt Disney (DIS), NVIDIA (NVDA), Tesla (TSLA) and AbbVie (ABBV).

Fund Details

• Issuer: Amplify
• Fund Name: Amplify Treatments, Testing and Advancements ETF
• Tax Classification: Regulated Investment Company
• Stock Exchange: NYSEARCA
• Current Symbol: NYSEARCA:GERM
• Inception Date: 6/17/2020
• Fund Manager: Charles Ragauss, Qiao Duan
• Web: N/A
• Phone: N/A

Fund Focus

• Asset Class: Equity
• Benchmark: Prime Treatments, Testing and Advancements Index
• Category: Strategy
• Focus: Theme
• Development Level: Blended Development
• Region: Global
• Number of Holdings: 2

Fund Statistics

• Assets Under Management: $9.67 million
• Average Daily Volume: $0.00
• Discount/Premium: -0.18%

Administrator, Advisor and Custodian

• Administrator: U.S. Bancorp Fund Services, LLC
• Advisor: Amplify Investments LLC
• Custodian: U.S. Bank, N.A.
• Distributor: Foreside Fund Services, LLC
• Transfer Agent: U.S. Bancorp Fund Services, LLC
• Trustee: N/A
• Lead Market Maker: Virtu Financial

Options

• Optionable: N/A
• Short Interest: 100 shs

Miscellaneous

• Outstanding Shares: 550,000
• Beta: 1.08
• Creation Unit: 50,000
• Creation Fee: $300.00